In prostate cancer, studies indicated that loss of DLGAP5 gene sensitizes androgen-dependent LNCaP cells to docetaxel treatment due to lower density of microtubule in their central spindles which requires a lower molecule content of drug to bind and stabilize the microtubule, suggesting that DLGAP5 may provide a potential novel target for chemotherapy efficacy [34]. Here, DLGAP5 is linked to prostate carcinoma.